Diagnostic criteria for oncocytic renal neoplasms:a survey of urologic pathologists by Williamson, Sean R. et al.
                                                              
University of Dundee
Diagnostic criteria for oncocytic renal neoplasms
Williamson, Sean R.; Gadde, Ramya; Trpkov, Kiril; Hirsch, Michelle S.; Srigley, John R.;
Reuter, Victor E.; Cheng, Liang; Priya Kunju, L.; Barod, Ravi; Rogers, Craig G.; Delahunt,
Brett; Hes, Ondrej; Eble, John N.; Zhou, Ming; McKenney, Jesse K.; Martignoni, Guido ;
Fleming, Stewart; Grignon, David J.; Moch, Holger; Gupta, Nilesh S.
Published in:
Human Pathology
DOI:
10.1016/j.humpath.2017.03.004
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Williamson, S. R., Gadde, R., Trpkov, K., Hirsch, M. S., Srigley, J. R., Reuter, V. E., ... Gupta, N. S. (2017).
Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Human Pathology, 63, 149-
156. https://doi.org/10.1016/j.humpath.2017.03.004
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
  	

Diagnostic Criteria for Oncocytic Renal Neoplasms: A Survey of Urologic
Pathologists
Sean R Williamson MD, Ramya Gadde MD, Kiril Trpkov MD, Michelle S.
Hirsch MD, PhD, John R Srigley MD, Victor E Reuter MD, Liang Cheng MD,
L Priya Kunju MD, Ravi Barod MD, Craig G Rogers MD, Brett Delahunt MD,
Ondrej Hes MD, John N Eble MD, Ming Zhou MD, PhD, Jesse K McKenney
MD, Guido Martignoni MD, Stewart Fleming MD, David J Grignon MD,
Holger Moch MD, Nilesh S Gupta MD
PII: S0046-8177(17)30076-X
DOI: doi: 10.1016/j.humpath.2017.03.004
Reference: YHUPA 4156
To appear in: Human Pathology
Received date: 9 January 2017
Revised date: 5 February 2017
Accepted date: 2 March 2017
Please cite this article as: Williamson Sean R, Gadde Ramya, Trpkov Kiril, Hirsch
Michelle S., Srigley John R, Reuter Victor E, Cheng Liang, Priya Kunju L, Barod Ravi,
Rogers Craig G, Delahunt Brett, Hes Ondrej, Eble John N, Zhou Ming, McKenney Jesse
K, Martignoni Guido, Fleming Stewart, Grignon David J, Moch Holger, Gupta Nilesh S,
Diagnostic Criteria for Oncocytic Renal Neoplasms: A Survey of Urologic Pathologists,
Human Pathology (2017), doi: 10.1016/j.humpath.2017.03.004
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Williamson et al – Criteria for oncocytic renal neoplasms 
 
 1 
Diagnostic Criteria for Oncocytic Renal Neoplasms: A Survey of Urologic 
Pathologists 
 
Sean R Williamson, MD
1,2,3 
Ramya Gadde, MD
1
 Kiril Trpkov, MD
4
 Michelle S. Hirsch, 
MD, PhD,
5
 John R Srigley, MD
6
 Victor E Reuter, MD
7
 Liang Cheng, MD
8
 L Priya Kunju, 
MD
9
 Ravi Barod, MD
10
 Craig G Rogers, MD
10
 Brett Delahunt, MD
11
 Ondrej Hes, MD
12
 
John N Eble, MD
8
 Ming Zhou, MD, PhD
13
 Jesse K McKenney, MD
14
 Guido Martignoni, 
MD
15,16
 Stewart Fleming, MD
17
 David J Grignon, MD
8
 Holger Moch, MD
18
 Nilesh S 
Gupta, MD
1,2
  
 
1
Department of Pathology and Laboratory Medicine and 
2
Henry Ford Cancer Institute, 
Henry Ford Health System, Detroit, MI, United States; 
3
Department of Pathology, Wayne 
State University School of Medicine, Detroit, MI, United States; 
4 
Department of 
Pathology and Laboratory Medicine, Calgary Laboratory Service and University of 
Calgary, Calgary, AB, Canada; 
5
Department of Pathology, Brigham and Women’s 
Hospital and Harvard Medical School, Boston, MA, United States; 
6
Department of 
Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; 
7
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 
United States; 
8 
Department of Pathology and Laboratory Medicine, Indiana University, 
Indianapolis, IN, United States; 
9
Department of Pathology, University of Michigan School 
of Medicine, Ann Arbor, MI, United States; 
10
Vattikutti Urology Institute, Henry Ford 
Health System, Detroit, MI, USA; 
11
Department of Pathology and Molecular Medicine, 
Wellington School of Medicine and Health Sciences, University of Otago – Wellington, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Williamson et al – Criteria for oncocytic renal neoplasms 
 
 2 
Wellington, New Zealand; 
12
Department of Pathology, Charles University in Prague, 
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ABSTRACT  
Renal oncocytoma and chromophobe renal cell carcinoma (RCC) have been long 
recognized as distinct tumors; however, it remains unknown if uniform diagnostic criteria 
are used to distinguish these tumor types in practice. A survey was distributed to urologic 
pathologists regarding oncocytic tumors. Responses were received from 17/26 invitees. 
Histologically, >1 mitotic figure was regarded as most worrisome (n=10) or incompatible 
(n=6) with oncocytoma diagnosis. Interpretation of focal nuclear wrinkling, focal 
perinuclear clearing, and multinucleation depended on extent and did not necessarily 
exclude oncocytoma if minor. Staining techniques most commonly used included: CK7 
(94%), KIT (71%), vimentin (65%), colloidal iron (59%), CD10 (53%), and AMACR 
(41%). Rare CK7-positive cells (≤5%) was regarded as most supportive of oncocytoma, 
although an extent excluding oncocytoma was not universal. Multiple chromosomal losses 
were most strongly supportive for chromophobe RCC diagnosis (65%). Less certainty was 
reported for chromosomal gain or a single loss. For tumors with mixed or inconclusive 
features, many participants use an intermediate diagnostic category (82%) that does not 
label the tumor as unequivocally benign or malignant, typically "oncocytic neoplasm" or 
"tumor" with comment. The term “hybrid tumor” was used variably in several scenarios. A 
slight majority (65%) report outright diagnosis of oncocytoma in needle biopsies. The 
morphologic, immunohistochemical, and genetic characteristics that define oncocytic renal 
tumors remain incompletely understood. Further studies correlating genetics, behavior, and 
histology are needed to define which tumors truly warrant classification as carcinomas for 
patient counseling and follow-up strategies. 
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INTRODUCTION 
 Renal oncocytoma[1] and chromophobe renal cell carcinoma[2,3] have been 
recognized for decades as unique renal tumor histologic subtypes, the former widely 
accepted as a benign neoplasm[4] and the latter largely considered a favorable renal cancer 
histology.[5] For the classic appearance of chromophobe renal cell carcinoma, there is little 
similarity to oncocytoma; however, it is well known that the eosinophilic variant[3] may 
cause a diagnostic challenge in distinguishing it from oncocytoma. Despite the fact that 
numerous techniques for differentiating these two tumor histologies have been explored 
over the years, including histochemical stains, immunohistochemistry, chromosomal 
changes, molecular assays, and electron microscopy,[6] it remains unknown if uniform 
diagnostic criteria are used by urologic pathologists in practice. 
MATERIALS AND METHODS 
 An online survey (SurveyMonkey.com, Palo Alto, CA, USA) was written by 5 of 
the authors (SRW, RG, RB, CGR, and NSG). Twenty-six urologic pathologists were 
invited to participate in the survey, based on 1) the perception by the survey authors of the 
invitees as substantially interested in tumors of the kidney, and 2) in an attempt to obtain a 
broad geographic distribution of academic urologic pathologists. The survey consisted of 
32 questions addressing histologic morphologic features, use of immunohistochemistry 
and other staining techniques, interpretation of molecular or chromosomal data, and 
reporting terminology, all of which are discussed as follows. Survey questions were based 
on text descriptions of histologic features and assay results (Figure 1), and therefore 
participants were not required to interpret images or stains. The study was carried out in 
accordance with The Code of Ethics of the World Medical Association (Declaration of 
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Helsinki) for experiments involving humans. Informed consent was obtained from the 
participants in the form that the intended use of the data was explained, and participants 
were given the option to withdraw participation at any time including at the completion of 
the survey or afterward. 
RESULTS 
 Seventeen participants completed the entire survey and were included in the 
dataset, including 2 of the survey authors (SRW and NSG). One invitee responded but 
declined to participate in the study, 1 survey response was incomplete (which was 
excluded), and no response was received from the remaining 7 invitees. Participants 
represented the United States (n=10), Canada (n=2), New Zealand (n=1), Czech Republic 
(n=1), Italy (n=1), United Kingdom (n=1), and Switzerland (n=1). Most participants (89%) 
confirmed evaluating >100 institutional renal tumors annually and many reported receiving 
personal consultation cases for opinion on renal tumors. Seven (41%) identified the kidney 
alone as their principle clinical or research interest, and the remainder reported the kidney 
in combination with one or more organs. 
Histologic Features 
 Most participants responded that a few binucleated cells (82%) or multinucleated 
cells (71%) were compatible with a diagnosis of oncocytoma. For “frequent” binucleated 
cells or multinucleated cells, responses shifted to a larger fraction of participants 
considering these findings worrisome for carcinoma, but not necessarily incompatible with 
an oncocytoma diagnosis (Figure 2). Less certainty was reported for a small amount 
(making up <5% of the tumor) of nuclear wrinkling or perinuclear cytoplasmic clearing. 
Half of participants (53%) considered <5% extent of perinuclear clearing to be compatible 
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with an oncocytoma diagnosis and 41% responded similarly for minor nuclear wrinkling 
(Figure 2). 
 A majority considered identification of a single mitotic figure upon careful search 
to remain compatible with oncocytoma diagnosis (82%), whereas more than one was 
considered more uniformly worrisome (59%) or incompatible (35%) with oncocytoma 
diagnosis. Just over half (59%) considered a few intranuclear cytoplasmic invaginations 
(pseudoinclusions) to be compatible with an oncocytoma diagnosis; however, with 
increasing extent, this finding was reported as increasingly worrisome for malignancy 
(47%, Figure 3). Most respondents indicated that focal cytoplasmic clearing within areas 
of hyalinized stroma (central scar) was compatible with an oncocytoma diagnosis (82%), 
and similarly for a few papillary tufts protruding into cystic spaces (76%). A predominant 
solid, compact growth pattern or trabecular growth pattern (absence of separate round 
nests) were most commonly regarded as worrisome for carcinoma (53% and 59%, 
respectively).  
Invasion of Structures 
 There was decreasing certainty for extension into structures as unequivocally 
compatible with an oncocytoma diagnosis, ranging from extension into perinephric fat[7-
10] (59%) to involvement of renal sinus fat (53%) to invasion of the renal vein or a vein 
branch[7,11,12] (35%, Figure 4).  
Special Staining and Immunohistochemistry 
 Respondents indicated they selectively use staining techniques in the differential 
diagnosis of oncocytoma, only when a specific differential diagnostic consideration is 
raised based on the histologic features (41%), usually in most cases (29%), in all cases 
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(24%, or combined 53% usually or always), and 6% rarely or never. The most commonly 
employed single antibody (94%) was cytokeratin 7 (CK7), although other commonly used 
techniques included KIT (71%), vimentin (65%), colloidal iron (Hale or modified Mowry 
methods, 59%), and CD10 (53%, Figure 5). Most participants (59%) reported that they 
perform succinate dehydrogenase (SDH) immunohistochemical staining only with unusual 
or borderline morphology (59%), or when morphology is highly suggestive of SDH-
deficient renal cell carcinoma (29%).[13,14] None of the participants reported screening 
oncocytic tumors routinely for SDH status.  
Staining Interpretation 
 Interpretation of staining results for CK7 is shown in Supplemental Tables 1-2 for 
diagnosis of oncocytoma (Supplemental Table 1) and chromophobe renal cell carcinoma 
(Supplemental Table 2). The largest majority of participants (82%) reported that CK7 
positivity in <5% of tumor cells would be supportive of oncocytoma, whereas an entirely 
negative staining result was less uniformly considered supportive (59%) but still 
considered compatible (Supplemental Table 1). Interpretation shifted to worrisome or 
incompatible with oncocytoma as extent increased. For chromophobe renal cell carcinoma, 
diffuse CK7 positivity was endorsed uniformly as supportive of the diagnosis (100%), but 
there was less certainty reported for negative or focal staining (Supplemental Table 2). 
Colloidal iron interpretation is shown in Supplemental Tables 3-4, and vimentin 
interpretation is shown in Supplemental Table 5.  
Genetic, Cytogenetic, and Molecular Assays 
 The largest fraction of respondents (41%) indicated that they have primarily used 
genetic, cytogenetic, or molecular assays for research purposes rather than clinical 
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diagnostics. Others reported using fluorescence in situ hybridization (FISH, 24%), 
conventional karyotyping (12%), or comparative genomic hybridization (6%) for 
diagnostic purposes. When interpreting genetic or cytogenetic changes, a majority (65%) 
endorsed losses of multiple chromosomes as supportive of chromophobe renal cell 
carcinoma diagnosis, whereas none (0%) reported that a single chromosomal loss was 
alone diagnostic of chromophobe renal cell carcinoma. Chromosomal gains were reported 
as supportive of chromophobe renal cell carcinoma diagnosis by 18%, whereas another 
24% interpreted this as supportive of an alternative diagnosis, such as renal cell carcinoma 
unclassified, “hybrid” tumor, or other.  
Borderline Cases   
When encountering a borderline renal tumor with a combination of morphology, 
immunohistochemistry, or genetics that is not perfect for an unequivocal diagnosis of 
either oncocytoma or chromophobe renal cell carcinoma, 53% of participants reported 
using a borderline or intermediate diagnostic category with comment explaining the 
differential diagnosis (neither diagnosed as carcinoma nor benign). Another 24% reported 
diagnosing such cases as unclassified renal cell carcinoma. Another 18% would report a 
diagnosis favoring one of these diagnoses, and 6% would err for diagnosis of 
chromophobe renal cell carcinoma when features are not perfect for oncocytoma. When 
asked specifically, 82% confirmed using in clinical practice (for a resection specimen) an 
intermediate diagnostic category that does not unequivocally label the tumor as malignant, 
whereas 18% reported not using such a diagnosis. Such diagnoses almost uniformly 
included as a base “oncocytic renal [cell] neoplasm” with varying modifier terms, such as 
“low-grade”, “borderline features”, “unclassified”, “low malignant potential”, “uncertain 
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malignant potential”, or “hybrid tumor”. A slightly smaller percentage of participants 
would support creation of an official term for this scenario (76%).  
 When queried as to use of the diagnosis of “hybrid tumor” or “hybrid oncocytoma-
chromophobe tumor”, the most reported usage (41%) was when discrete areas of the tumor 
show typical features of oncocytoma and other areas show typical features of chromophobe 
renal cell carcinoma, regardless of whether a syndrome (such as Birt-Hogg-Dubé or renal 
oncocytosis) is known. Others reported using this term: never (18%); for any borderline 
tumor regardless of a syndrome (18%); only in the setting of a syndrome or apparent 
syndrome (12%); both in borderline cases and those with discrete areas of different 
morphology (6%); and rarely (6%) with a description of specific morphology provided.   
Biopsy Diagnosis 
 A slight majority of participants would issue an outright diagnosis of oncocytoma 
in a needle biopsy specimen (64%). Of those that were unwilling to diagnose unequivocal 
oncocytoma in a biopsy sample (35%), diagnoses primarily were variations of “oncocytic 
neoplasm [or tumor], favor [or consistent with] oncocytoma”. 
Malignant Behavior of Oncocytoma-Like Neoplasms 
 Most participants (82%) reported never having encountered a tumor that closely 
mimicked an oncocytoma, yet which metastasized, whereas 3 (18%) reported encountering 
this scenario in a small number of cases over their careers.  
  
DISCUSSION 
  Renal oncocytoma and chromophobe renal cell carcinoma are well recognized as 
distinctive renal cell tumors; however, challenges related to their pathologic diagnosis have 
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persisted since their recognition.[1-3] A wide array of biomarkers have been investigated 
for distinguishing these two tumor types;[6] however, how these are employed and 
interpreted in practice remains incompletely understood.[15] Although chromophobe renal 
cell carcinoma is generally accepted as an indolent form of renal cancer,[5] distinction 
from oncocytoma is not trivial, as it carries a potential psychological burden of a cancer 
diagnosis and healthcare costs and radiation exposure from surveillance.[16-19] This 
distinction also has implications for patient management, such as preoperative diagnosis 
via tumor biopsy[20-24] and imaging surveillance rather than resection.[25] Adjuvant 
therapy is currently not routinely employed after resection of localized renal cell 
carcinomas; however, enrollment in clinical trials may be dependent on this differential 
diagnosis, such as for oncocytic tumors with involvement of fat or blood vessels, for which 
the considerations would be between a benign tumor (oncocytoma) and high-stage (pT3a) 
renal cell carcinoma.  
 Regarding histologic features, the finding that emerged in this study as most 
worrisome for excluding an oncocytoma diagnosis was the presence of more than 1 
identifiable mitotic figure, whereas 82% of participants felt that identification of a single 
mitotic figure upon careful search remained compatible with a diagnosis of oncocytoma 
(Figure 3). For other features characteristically associated with chromophobe renal cell 
carcinoma, such as binucleation, multinucleation, nuclear irregularities, perinuclear 
clearing, and intranuclear cytoplasmic invaginations, there was less certainty reported, and 
in general interpretation as compatible with oncocytoma diagnosis decreased with the 
extent of these features (Figures 2 and 3).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Williamson et al – Criteria for oncocytic renal neoplasms 
 
 12 
 Several studies have reported that perinephric fat extension can occur with 
oncocytoma, without an apparent adverse effect on the benign behavior.[7-10] However, 
some concern persists regarding this finding, with only 59% of participants responding 
“compatible with oncocytoma diagnosis” and 41% considering it worrisome but not 
necessarily incompatible with oncocytoma. This decreased slightly to 53% for renal sinus 
fat involvement, which is well-known as an invasive pathway in clear cell renal cell 
carcinoma,[26] but has not been thoroughly studied in oncocytoma. A few studies have 
reported that vascular invasion, including renal vein invasion or renal vein branch 
invasion, does not necessarily alter the benign behavior of oncocytoma;[7,11,12] however, 
acceptance of this as compatible with oncocytoma decreased to 35%, with 41% 
considering it worrisome, and 24% considering it incompatible with a diagnosis of 
oncocytoma. We did not specifically assess whether the participants were aware of the 
literature supporting the benign behavior in this context or whether they felt the literature 
was not definitive; however, notably the largest study on this latter phenomenon [12] has 
only become published in the interim since the data for the current survey were already 
collected.  
 With regard to staining techniques, CK7 was reported as the most commonly used 
immunohistochemical antibody for oncocytoma diagnosis (94%). Surprisingly, the existing 
literature on this antibody demonstrates disparate results, with some studies reporting 
consistent positivity in oncocytoma and others reporting negative, or largely negative, 
results.[6] We suspect that this reflects threshold selection, as the vast majority of the 
tumor cells in oncocytoma are negative, with scattered positivity only in single cells and 
small clusters of cells.[15] If a binary reporting system is used, this could be interpreted as 
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either negative or positive, depending if a cutoff is used, or if any staining is defined as 
positive. The largest fraction of respondents (82%) interpreted focal staining of <5% of 
cells as supportive of oncocytoma. With increasing extent of CK7 positivity, interpretation 
in favor of oncocytoma decreased (Supplemental Table 1), although there was not 
agreement on an amount of positivity that excluded oncocytoma. For chromophobe renal 
cell carcinoma, diffuse CK7 positivity was endorsed as supportive of the diagnosis 
(100%), but there was less certainty reported for negative or focal staining (Supplemental 
Table 2). In general, negative colloidal iron staining was considered supportive of 
oncocytoma, and there was less certainty for partial staining patterns, such as an apical 
“bar” of staining[27] or other patterns (Supplemental Table 3). 
 Regarding chromosomal changes, oncocytomas often exhibit a diploid karyotype, 
loss of chromosome 1 or 14, or a few recurring rearrangements.[4] Conversely, 
chromophobe renal cell carcinoma is characterized by multiple losses of chromosomes, 
including 1, 2, 6, 10, 13, 17, 21, and Y.[5] The recent Cancer Genome Atlas analysis, 
however, noted that fewer such losses are found in eosinophilic variant chromophobe renal 
cell carcinoma.[28] Some studies have found that so-called “hybrid oncocytoma-
chromophobe tumors” and the neoplasms of renal oncocytosis may have chromosomal 
gains as well as losses,[29,30] and similarly a combination of gains and losses has been 
also reported in usual chromophobe renal cell carcinoma.[31] As such we also queried the 
participants interpretation of chromosomal and genetic findings in this scenario. The 
greatest support was reported for multiple losses as supportive of chromophobe renal cell 
carcinoma (65%), whereas a single chromosome loss (excluding chromosome 1, since this 
is a shared finding with oncocytoma) was not considered inherently diagnostic of 
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chromophobe alone. There was no clear consensus for interpretation of chromosomal 
gains.  
 In cases with borderline features that are difficult to distinguish between 
oncocytoma and eosinophilic variant chromophobe renal cell carcinoma, a considerable 
majority of the urologic pathology specialists in this study were willing to use a borderline 
diagnostic category (82%) that does not label the tumor as unequivocally benign or 
malignant. Such diagnoses typically included as a base “oncocytic renal [cell] neoplasm” 
with varying modifier terms, such as “low-grade”, “borderline features”, “unclassified”, 
“low malignant potential”, “uncertain malignant potential”, or “hybrid tumor”. This study 
also revealed that there is some variability in the use of the term “hybrid tumor,” or 
“hybrid oncocytoma-chromophobe tumor (HOCT),” which is used by pathologists in 
several scenarios: discrete mosaic or mixed morphology (41%), for any borderline tumor 
regardless of a syndrome (18%), only in the setting of a syndrome or apparent syndrome 
(12%), or never (18%). The current World Health Organization Classification discusses the 
occurrence of such “hybrid” tumors under the heading of chromophobe renal cell 
carcinoma;[32] however, it remains debated whether such tumors occurring with tumor 
syndromes and sporadically represent one or more distinct entities.[33]  
 Renal mass biopsy is increasingly important in clinical practice to guide 
management of renal tumors and to aid in consideration of various treatment options.[20-
25] A slight majority of participants (64%) indicated willingness to diagnose oncocytoma 
outright by needle biopsy; however, those that do not (35%) typically diagnose “oncocytic 
neoplasm [or tumor], favor [or consistent with] oncocytoma”. Regardless of the 
terminology used, clear communication and understanding between pathologists and 
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clinical colleagues is necessary to ensure appropriate management. As an example, some 
pathologists may use a diagnosis of unclassified renal cell carcinoma for an oncocytic 
tumor that cannot be categorized as either an oncocytoma or chromophobe renal cell 
carcinoma (24% in this survey). This approach reflects that the tumor that does not fit well 
into a defined category; however, a clear qualifier or discussion with clinicians would be 
warranted to convey that aggressive behavior is not suspected in light of the close 
resemblance to, and differential diagnosis with, oncocytoma and chromophobe renal cell 
carcinoma. Without such a qualifier or discussion, there may be a perception that 
unclassified renal cell carcinoma is highly aggressive,[34,35] which may be relevant to the 
role of adjuvant therapy in clinical trials. In contradistinction, despite that the academic 
uropathologists surveyed in this study reported evaluating a relatively large number of 
renal tumors, very few reported ever encountering a tumor that closely resembled 
oncocytoma that metastasized, which is mirrored by the lack of well-documented cases in 
the recent literature.  
 Limitations of the current survey are that it only queries the current state of this 
challenging area of diagnostics rather than establishing definitive guidelines. Of course, is 
not appropriate to define diagnostic criteria based purely on consensus opinion, in the 
absence of outcome data. Unfortunately, it may be challenging to collect an adequate 
number of metastatic oncocytic renal tumors, even interinstitutionally. It is also a 
limitation that only 17 of 26 invitees ultimately participated in the study, such that a 
considerable fraction (35%) of urologic pathologists perceived as interested in renal tumors 
were not sampled.   
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As there remains some variability and uncertainty in what defines oncocytoma, 
additional studies correlating genetics, outcome, and histology are needed to define which 
tumors truly warrant classification as carcinomas for patient counseling and follow-up 
strategies, especially now, entering the era of genomics and personalized medicine. The 
results of this study may nonetheless be helpful to general surgical pathologists in 
highlighting the potential use of a borderline category for some renal oncocytic tumors, 
and illustrating the few staining techniques that are most regularly employed by urologic 
pathologists in this scenario. 
 
Acknowledgment: The authors would like to thank Dr. Lars Egevad for suggestions 
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Figure Legends: 
Figure 1: Examples of challenging diagnostic features of oncocytic renal cell neoplasms: 
(A) In this core needle biopsy of an oncocytic renal tumor (20× magnification, 
hematoxylin and eosin), the cells have voluminous cytoplasm and a lower nuclear-
cytoplasmic ratio, resembling chromophobe renal cell carcinoma; however, 
immunohistochemical staining characteristics were similar to those of oncocytoma, 
including minimal cytokeratin 7 labeling (not pictured). (B) In this core needle biopsy (10× 
magnification, hematoxylin and eosin), tumor cell cytology resembles that of oncocytoma; 
however, there is a trabecular rather than nested appearance. (C) This tumor diagnosed as 
oncocytoma demonstrates perinephric fat extension (10× magnification, hematoxylin and 
eosin). (D) This tumor was interpreted as oncocytoma, but it extends into the lumen of a 
large vein, with a thin vein wall at left and only an endothelial layer surrounding the tumor 
cells (10× magnification, hematoxylin and eosin). (E) This oncocytic neoplasm contains 
cells with uniform round nuclei (40× magnification, hematoxylin and eosin); however, 
there are scattered binucleated cells and there is minor perinuclear clearing (“halo”). (F) 
The same tumor demonstrates diffuse labeling for cytokeratin 7 (10× magnification, anti-
cytokeratin 7 immunohistochemistry).  
 
Figure 2: Survey responses for histologic features in relation to diagnosis of oncocytoma. 
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Figure 3: Survey responses for histologic features in relation to diagnosis of oncocytoma. 
 
Figure 4: Survey responses for invasion of perinephric fat, renal sinus fat, and vein 
invasion in relation to diagnosis of oncocytoma 
 
Figure 5: Staining techniques used by the survey participants in differential diagnosis of 
oncocytic renal tumors.  
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